Year: 2019
Type: article
Abstract: Gene therapies using adeno-associated viral (AAV) vectors have advanced into clinical trials for several diseases, including Duchenne muscular dystrophy (DMD). A limitation of AAV is the carrying capacity (∼5 kb) available for genes and regulatory cassettes (RCs). These size constraints are problematic for the 2.2-Mb dystrophin gene. We previously designed a variety of miniaturized micro-dystrophins (μDys) that displayed significant, albeit incomplete, function in striated muscles. To develop μDys proteins with improved performance, we explored structural modifications of the dystrophin central rod domain. Eight μDys variants were studied that carried unique combinations of between four and six of the 24 spectrin-like repeats present in the full-length protein, as well as various hinge domains. Expression of μDys was regulated by a strong but compact muscle-restricted RC (CK8e) or by the ubiquitously active cytomegalovirus (CMV) RC. Vectors were evaluated by intramuscular injection and systemic delivery to dystrophic mdx 4cv mice, followed by analysis of skeletal muscle pathophysiology. Two μDys designs were identified that led to increased force generation compared with previous μDys while also localizing neuronal nitric oxide synthase to the sarcolemma. An AAV vector expressing the smaller of these (μDys5) from the CK8e RC is currently being evaluated in a DMD clinical trial.
Source: Molecular Therapy
Authors: Julian N. Ramos(Formal analysis, Investigation, Methodology, Visualization, Writing – original draft), Katrin Hollinger(Formal analysis, Investigation, Methodology, Visualization), Niclas E. Bengtsson(Formal analysis, Investigation, Methodology), James M. Allen(Investigation, Methodology, Supervision), Stephen D. Hauschka(Conceptualization, Formal analysis, Supervision, Writing – review & editing), Jeffrey S. Chamberlain(Conceptualization, Formal analysis, Methodology, Supervision, Writing – review & editing)
Institution: University of Washington
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,500
Funders: Muscular Dystrophy Association, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of General Medical Sciences, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: Sen Paul D. Wellstone Muscular Dystrophy Cooperative Research Center: Seattle, Intellectual and Developmental Disabilities Research Center, Training in Cellular and Molecular Biology, Therapeutic potential for AAV/micro-dystrophin transfer to cardiopulmonary tissue, G9000277929, Dystrophin Replacement, Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center - Seattle
OpenAlex ID: W2912811937
